clinical trial · NCT07161037
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Vertex Pharmaceuticals Incorporated·phase2·recruiting·n = 24
Autosomal Dominant Polycystic Kidney Disease (ADPKD)VX-407
brief summary
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
started
Nov 19, 2025
primary completion
Jul 22, 2027
completion
Dec 31, 2027
last updated
Jun 15, 2026
official title
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol